Cargando…
HIV-1 vaccine immunogen design strategies
An effective human immunodeficiency virus type 1 (HIV-1) vaccine is expected to have the greatest impact on HIV-1 spread and remains a global scientific priority. Only one candidate vaccine has significantly reduced HIV-1 acquisition, yet at a limited efficacy of 31%, and none have delayed disease p...
Autores principales: | Mann, Jaclyn K, Ndung’u, Thumbi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318220/ https://www.ncbi.nlm.nih.gov/pubmed/25616599 http://dx.doi.org/10.1186/s12985-014-0221-0 |
Ejemplares similares
-
The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19
por: Mann, Jaclyn Kelly, et al.
Publicado: (2020) -
Genetic determinants of Nef-mediated CD4 and HLA class I down-regulation differences between HIV-1 subtypes B and C
por: Mann, Jaclyn K., et al.
Publicado: (2015) -
Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles
por: Moyano, Ana, et al.
Publicado: (2023) -
Partial compartmentalisation of HIV-1 subtype C between lymph nodes, peripheral blood mononuclear cells and plasma
por: Jeewanraj, Neschika, et al.
Publicado: (2023) -
Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses
por: Luthuli, Bonisile, et al.
Publicado: (2023)